Paratek Pharmaceuticals
Developing transformative solutions for patients with infectious diseases.
Launch date
Employees
Market cap
€120m
Enterprise valuation
€324m (Public information from Sep 2023)
Share price
€2.024 N4CN.F
Boston Massachusetts (HQ)
Financials
Estimates*
USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | - | 12.6m | 17.1m | 16.5m | 43.5m | 121m | 151m |
% growth | - | - | 36 % | (3 %) | 163 % | 178 % | 25 % |
EBITDA | - | (82.0m) | (101m) | (112m) | (73.9m) | (40.7m) | (44.9m) |
% EBITDA margin | - | (650 %) | (589 %) | (678 %) | (170 %) | (34 %) | (30 %) |
Profit | - | (89.1m) | (112m) | (129m) | (96.5m) | (59.1m) | (63.6m) |
% profit margin | - | (706 %) | (656 %) | (778 %) | (222 %) | (49 %) | (42 %) |
EV / revenue | - | 32.3x | 8.3x | 10.8x | 9.4x | 1.5x | 1.2x |
EV / EBITDA | - | -5.0x | -1.4x | -1.6x | -5.6x | -4.5x | -4.0x |
R&D budget | 86.9m | 60.1m | 57.5m | 39.6m | 23.9m | 30.4m | 37.8m |
R&D % of revenue | - | 476 % | 336 % | 239 % | 55 % | 25 % | 25 % |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
$40.0m | Post IPO Equity | ||
$93.0m | Post IPO Debt | ||
* | N/A | $71.1m | Post IPO Equity |
$60.0m | Post IPO Debt | ||
* | $472m Valuation: $472m 3.1x EV/LTM Revenues -10.5x EV/LTM EBITDA | Acquisition | |
Total Funding | - |
Related Content
Recent News about Paratek Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Paratek Pharmaceuticals
EditACQUISITION by Paratek Pharmaceuticals Oct 2014